부산대학교 도서관

Tanja Plate,1 Felix W Friedrich,1 Jutta Beier2 1AstraZeneca GmbH, Wedel, Germany; 2Insaf - Respiratory Research Institute GmbH, Wiesbaden, GermanyCorrespondence: Felix W FriedrichAstraZeneca GmbH, Tinsdaler Weg 183, Wedel D-22880, GermanyTel +49 162 1398835Fax +49 4103 70873707Email felix.friedrich@astrazeneca.comBackground: LABA (long-acting β 2-agonists) and/or LAMA (long-acting muscarinic antagonists) represent the first treatment options for patients with symptomatic COPD. Although both display different mechanisms of activity, in combination they have a stronger broncho-dilating effect than monotherapy; hence, a combination of both LABA and LAMA is particularly recommended for patients whose symptoms cannot be sufficiently improved by a single active ingredient. To date, only few data have been collected regarding the therapeutic outcomes of approved LABA/LAMA fixed-dose combinations (FDCs) under everyday (real-life) conditions in non-clinical trial settings.Objective and Methods: The main objective of the DETECT study was to investigate the impact of aclidinium/formoterol (AB/FF, b.i.d.), glycopyrronium/indacaterol (GLY/IND, q.d.) and umeclidinium/vilanterol (UME/VL, q.d.) in patients with COPD in daily clinical practice. Therefore, a prospective, non-randomized, 12-month, observational study was implemented to assess the effectiveness of these treatments in patients who had been switched to FDC within the last 3 months or for whom such a changeover was intended. Changes in lung function were analyzed by the forced expiratory volume (FEV1) and forced vital capacity (FVC) measures. Quality of life and well-being were evaluated by the COPD Assessment Test (CAT™). Furthermore, a number of exacerbations and early morning COPD symptoms were documented.Results: In total, 3653 patients were enrolled. FEV1 and FVC values significantly improved during the study with AB/FF (increase by 0.09 ± 0.40 L and 0.10 ± 0.57 L, respectively; p< 0.0001), GLY/IND (0.06± 0.38/0.05± 0.51 L; p< 0.0001 and p=0.0025) and UME/VL (0.12± 0.39/0.10± 0.52 L; p< 0.0001). CAT scores decreased indicating improved COPD (AB/FF, 4.17± 8.30; GLY/IND, 3.66± 7.88; UME/VL, 4.06± 7.96; p< 0.0001). Moreover, the number of exacerbations as well as early morning COPD symptoms similarly diminished in all treatment groups. A comparable proportion of patients with adverse drug reactions was recorded: AB/FF, 4.07% of patients; GLY/IND, 3.52%; UME/VL, 3.64%.Conclusion: In summary, AB/FF, GLY/IND and UME/VL provided clinical benefits in lung function, quality of life and early morning COPD symptoms in a broad cohort of COPD patients under routine medical practice conditions. All three treatments were well tolerated.Keywords: chronic obstructive pulmonary disease, combination therapy, bronchodilators, chronic bronchitis, long-acting muscarinic antagonists, long-acting β2-agonists